Welcome to our dedicated page for Bioxytran SEC filings (Ticker: BIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bioxytran, Inc. filings document the disclosure record of a Nevada clinical-stage biotechnology company developing carbohydrate-based therapeutics and galectin-targeting technologies. Its Form 8-K reports cover clinical updates for ProLectin-M, the A-SUQAR® distribution agreement, and private placements of common stock and warrants for working capital and general corporate purposes.
The company’s filings also address capital-structure and governance matters, including amendments to Convertible Preferred Stock conversion provisions, equity compensation, officer and director changes, and internal-control and approval-process reviews. Its Form 12b-25 notice documents late annual-report timing tied to audit completion and financial-statement disclosure revisions.
Bioxytran, Inc. reported a net loss of $2,068,989 for the three months ended March 31, 2026, or $0.02 per share, unchanged from the prior year’s loss per share. The company generated no revenue and remains a clinical-stage pharmaceutical developer.
Cash totaled $463,047 against current liabilities of $5,010,121, creating a negative working capital position of $4,547,075 and an accumulated deficit of $23,113,235, which raises substantial doubt about its ability to continue as a going concern. Bioxytran relies on equity and warrant financings and carries a defaulted $805,000 convertible note with an associated derivative liability of $476,489, pointing to significant potential dilution.
During the quarter, operating expenses rose sharply to $1,933,053, driven largely by $1,290,015 of stock-based compensation, including a substantial performance grant to the CEO. The company highlights statistically significant Phase 1b/2a data for its COVID-19 candidate ProLectin-M and plans Phase 3 and FDA trials, but indicates that advancing these programs depends on raising additional capital.
Bioxytran, Inc. files its annual report describing a clinical-stage biotech focused on glycovirology antivirals and oxygen-delivery drugs for hypoxia and stroke. The company highlights Phase 2 data for its oral COVID-19 candidate ProLectin-M and preclinical work on its BXT-25 oxygen carrier.
Bioxytran reports an aggregate market value of non-affiliate voting stock of about $9.3 million and 113.4 million common shares outstanding. Management expects to incur losses for the foreseeable future and estimates it will need roughly $30–35 million of additional funding to advance key programs through mid- to late-stage trials.
Bioxytran, Inc. notified the SEC that it cannot file its Annual Report on Form 10-K for the period ended December 31, 2025 on time because a small accounting staff required additional time to incorporate significant last-minute auditor revisions. The company states it expects to file within the 15-day grace period under Rule 12b-25. The notice is signed by Ola Soderquist, Chief Financial Officer, on March 31, 2026.
Bioxytran, Inc. completed a private placement of common stock and warrants, raising approximately $1.2 million in gross proceeds. The company issued about 21,071,667 common shares at $0.055 per share and warrants to purchase up to 19,750,001 additional shares at $0.12 per share, exercisable immediately for five years.
Bioxytran plans to use the net proceeds for working capital and general corporate purposes, including advancing its clinical and development programs and selected commercialization initiatives. Management highlighted a dual-track strategy that combines near-term commercialization, including the planned launch this quarter of its A-SUQAR dietary supplement, with longer-term pharmaceutical development based on its galectin-targeting platform.
Bioxytran, Inc. reported governance and compensation changes related to its Convertible Preferred Stock. The company amended the Certificate of Designation so that any conversion of Convertible Preferred Stock into common stock now requires approval by both the Board of Directors and a majority of outstanding preferred shareholders voting as a single class. This amendment was filed with the Nevada Secretary of State on February 18, 2026 and became effective upon filing. The Board also granted 6,000,000 shares of Convertible Preferred Stock to Chief Executive Officer David Platt as a performance-based equity award, recognizing his role in executing the company’s first commercial distribution agreement and advancing capital funding initiatives, and aiming to align his incentives with commercialization and capital formation objectives.
Bioxytran, Inc. filed an 8-K to share positive early clinical data for its oral antiviral ProLectin-M in mild to moderate COVID-19. In a randomized, double-blind, placebo-controlled Phase 1b/2a study of 39 hospitalized patients in India, the highest dose of ProLectin-M (16,800 mg/day) plus standard of care led to earlier viral clearance and faster clinical improvement than placebo.
By Day 5, 90% of patients at the highest dose had non-detectable viral shedding, compared with 20.0% on placebo and 20.0% and 40.0% on the lower-dose arms, with a statistically significant difference versus placebo (p=0.001). The same 90% of patients at the highest dose achieved at least a 2-point improvement on the WHO Ordinal Scale by Day 5, versus 20.0–40.0% in other groups, and all patients improved by Day 7 as the infection naturally resolved.
No serious adverse events, treatment-related discontinuations, or clinically meaningful safety issues were reported, and compliance with the 5-day regimen was high. ProLectin-M targets galectins, host carbohydrate-binding proteins involved in viral attachment and entry, offering a differentiated mechanism that might apply across multiple viral infections. The company states that these data support continued development of ProLectin-M in larger, well-controlled studies.
Bioxytran, Inc. entered into a commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR®, a chewable dietary supplement using Bioxytran’s proprietary partially hydrolyzed guar gum formulation. Khoury Medical will handle regulatory registration, marketing, and distribution in permitted markets, while manufacturing will be done by a Bioxytran-designated manufacturer and Bioxytran retains full intellectual property ownership.
The product is positioned as a dietary supplement intended to support healthy post-meal blood sugar levels, consistent with regulatory requirements. The agreement applies only to non-pharmaceutical dietary products, preserving Bioxytran’s ability to develop pharmaceutical and antiviral programs, including those based on its galectin-targeting platform and its investigational antiviral ProLectin-M. The parties expect initial commercial shipments after completion of standard launch preparations.
Bioxytran, Inc. reported positive Phase 2 results for its oral antiviral candidate ProLectin-M in an acute viral infection study. In a 38-subject randomized, double-blind, placebo-controlled, dose-optimization trial, 100% of treated subjects achieved complete elimination of viral load by Day 7 versus placebo (p = .001), with no viral rebounds during a 14-day observation period.
Viral clearance was assessed by RT-PCR of nasopharyngeal swabs, and dose selection was refined to four tablets per day. The company plans to advance regulatory discussions and explore additional viral indications consistent with ProLectin-M’s described broad-spectrum antiviral profile and its extracellular, galectin-antagonist mechanism of action.
Bioxytran, Inc. reported that effective December 29, 2025, Mike Sheikh was terminated as an officer of the company. The filing does not describe his specific role or responsibilities, but notes that his separation is formally effective on that date. In a letter dated December 31, 2025, Mike Sheikh is contesting the reason for his dismissal, and this dispute is identified as a factor in determining any severance benefits. The report does not provide additional financial information or changes to the company’s operations beyond this leadership change.
Bioxytran, Inc. reported that director Anders Utter resigned from its Board and as Chair of the Audit Committee, effective December 7, 2025.
In his resignation letter, he said he had recommended stronger oversight, internal controls, and approval processes, including better segregation of duties, clearer documentation of material contractual and financial approvals, and legal review of a recent stock issuance. He noted that some recommendations were not adopted or were interpreted differently than intended and that greater alignment on governance practices was needed.
The company has engaged an independent third-party financial expert to review its oversight, internal control, and approval processes and to provide recommendations to the Board, and, if approved, assist in implementing them. It also stated that Mr. Utter did not cite any disagreement with its financial statements, accounting practices, or SEC disclosures.